The pharmacokinetics of N, N-bis(2-mercapatoethly)- N', N'-diethylenediamine (BMEDA), a molecule that can form a chelate with rhenium-188 ( 188Re) to produce the 188Re-BMEDA-liposomes, was studied. In this work, beagles received a single injection of BMEDA, at doses of 1, 2, or 5 mg/kg; the concentration of BMEDA in the beagles’ plasma was then analyzed and determined by liquid chromatography-mass spectrometry/mass spectrometry. Based on the pharmacokinetic parameters of BMEDA, we found that male and female animals shared similar patterns indicating that the pharmacokinetics of BMEDA is independent of gender differences. In addition, the pharmacokinetics of BMEDA was seen to be non-linear because the increase of mean AUC 0–t and AUC 0–∞ values tend to be greater than dose proportional while the mean Vss and CL values of BMEDA appeared to be dose dependent. The information on the pharmacokinetics of BMEDA generated from this study will serve as a basis to design appropriate pharmacology and toxicology studies for future human use.
Lombardi, L.; Morelli, F.; Cinieri, S.; Santini, D.; Silvestris, N.; Fazio, N.; Orlando, L.; Tonini, G.; Colucci, G.; Maiello, E. Adjuvant colon cancer chemotherapy: Where we are and where we’ll go. Cancer Treat. Rev. 2010, 36, S34–S41, doi:10.1016/S0305-7372(10)70018-9.
Hamoudeh, M.; Kamleh, M.A.; Diab, R.; Fessi, H. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv. Drug Deliv. Rev. 2008, 60, 1329–1346, doi:10.1016/j.addr.2008.04.013.
Bao, A.; Goins, B.; Klipper, R.; Negrete, G.; Mahindaratne, M.; Phillips, W.T. A novel liposome radiolabeling method using 99mTc-“SNS/S” complexes: In vitro and in vivo evaluation. J. Pharm. Sci. 2003, 92, 1893–1904, doi:10.1002/jps.10441.
Schary, W.L.; Rowland, M. Protein binding and hepatic clearance: Studies with tolbutamide, a drug of low intrinsic clearance, in the isolated perfused rat liver preparation. J. Pharmacokinet. Biopharm. 1983, 11, 225–243, doi:10.1007/BF01061866.
Levy, G.; Tsuchiya, T.; Amsel, L.P. Limited capacity for salicyl phenolic glucuronide formation and its effect on the kinetics of salicylate elimination in man. Clin. Pharmacol. Ther. 1972, 13, 258–268.